The pharma began submitting its TAR-200 bladder cancer treatment to the FDA. Elsewhere, Sarepta and Madrigal reported strong ...

While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his ...

The review, which was spurred by controversy over the FDA's Aduhelm approval, recommends two main changes in agency ...

Faro Health Inc., the leading AI-powered platform for data-driven clinical protocol design, today announced it has partnered with Recursion (NASDAQ: RXRX) to accelerate and optimize clinical protocol ...

NULISA employs a sequential immunocomplex capture and release technique to improve the sensitivity of traditional proximity ...